Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

Scientific and political discussions around the role of animal-source foods (ASFs) in healthy
and environmentally sustainable diets are often polarizing. To bring clarity to this important …

Background: Genetic loss-of-function variants in ANGPTL3 are associated with lower levels
of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits …

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …

Background: It remains unclear if a low-carbohydrate, high-fat (LCHF) diet is a possible
treatment strategy for type 2 diabetes mellitus (T2DM), and the effect on nonalcoholic fatty …

In 2019, the European Society of Cardiology/European Atherosclerosis Society stated that
apolipoprotein B (apoB) was a more accurate marker of cardiovascular risk than low‐density …

Aims The strength of the relationship of triglyceride-rich lipoproteins (TRL) with risk of
coronary heart disease (CHD) compared with low-density lipoprotein (LDL) is yet to be …

Embraced with apolipoproteins (Apo) B and Apo E, triglyceride-enriched very-low-density
lipoprotein (VLDL) is secreted by the liver into circulation, mainly during post-meal hours …

Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk.
Whether apoB levels and apoB lowering hold incremental predictive information on residual …

In 1979, Avogaro et al1 reported that apolipoprotein B (apoB) was a more accurate marker
of the risk of a myocardial infarction than total cholesterol. In 1980, Sniderman et al2 …